Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S15-S29 , December 2006

Aromatase inhibitors: effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer

  • Louis Mauriac (Medical Oncologist)

      Affiliations

    • Corresponding Author InformationTel.: +33 5 56 33 32 58; Fax: +33 5 56 33 33 85.

References 

  1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–1717
  2. Fisher B, Dignam J, Bryant J, et al. Five years versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute. 1996;88:1529–1542
  3. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology. 1996;14:2738–2746
  4. Lønning PE. Aromatase inhibition for breast cancer treatment. Acta Oncologica (Stockholm, Sweden). 1996;35(supplement 5):S38–S43
  5. Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer. 2002;95:2006–2016
  6. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. 1998;16:453–461
  7. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clinical Oncology. 2000;18:1399–1411
  8. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology. 1996;14:2000–2011
  9. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology. 2003;21:2101–2109
  10. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–2258
  11. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 2003;14:1391–1398
  12. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology. 2001;19:3357–3366
  13. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology. 2001;12:1527–1532
  14. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology. 2005;23:5108–5116
  15. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139Erratum in: Lancet 2002; 360: 1520
  16. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  17. Arimidex Prescribing Information. www.arimidex.comAccessed 11 July 2006
  18. Howell A on behalf of the ATAC Trialists' Group. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Breast Cancer Research and Treatment. 2004;88:S5;(abstract 1). Available online: http://www.sabcs.org/SymposiumOnline/index.asp#webcast
  19. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology. 2005;23:7512–7517
  20. Thürlimann B on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine. 2005;353:2747–2757
  21. Viale G, Regan M, Dell'Orto P, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 44)
  22. Camp RL, Dolled-Filhart M, King BL, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Research. 2003;63:1445–1448
  23. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clinical Cancer Research. 2003;9:1039–1046
  24. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research. 2003;63:6523–6531
  25. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England Journal of Medicine. 2004;350:1081–1092Erratum in: The New England Journal of Medicine 2004; 351: 2461
  26. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology. 2005;23:5138–5147
  27. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  28. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Research and Treatment. 2005;94(supplement 1):(abstract 13). Available online: http://www.sabcs.org/SymposiumOnline/index.asp#webcast
  29. Mauriac L, Keshaviah A, Debled M, et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. EJC Supplements. 2006;4:111;Available online: http://www.ibcsg.org/public/documents/pps/trial_18-98/EBCC_Mauriac_BIG1-98.ppt
  30. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology. 2005;16:1569–1583
  31. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. Journal of the National Comprehensive Cancer Network. 2005;3:309–314
  32. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology. 2005;23:619–629
  33. Perez EA. The balance between risks and benefits: long-term use of aromatase inhibitors. European Journal of Cancer Supplement. 2006;4(9):16–25
  34. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001;11:95–102
  35. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine. 2003;18:937–947
  36. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 2005;97:1262–1271
  37. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology. 2003;30:763–775
  38. Brufsky A, Harker W, Beck J, et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Journal of Clinical Oncology. 2005;23:12s;(abstract 533)
  39. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). European Journal of Cancer Supplement. 2006;4:48;(abstract 12)
  40. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. Journal of Clinical Oncology. 2004;22:4261–4271
  41. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology. 2006;24:910–917
  42. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology. 2005;23:6931–6940

PII: S1521-690X(06)00082-0

doi: 10.1016/j.beem.2006.10.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20 , Pages S15-S29 , December 2006

Article Tools

* Image Usage & Resolution